Journal of Biological Chemistry Impact Factor

JBC's IF (3.9) is lower than Molecular Cell (16.6) or EMBO Journal (9.4), but the comparison is misleading. JBC publishes ~2,500 papers per year across all of biochemistry. Molecular Cell publishes ~200 highly selective papers. JBC's strength is its breadth and accessibility.

The five-year JIF (4.3) running above the two-year (3.9) shows JBC papers have lasting citation value. Biochemistry is a field where detailed mechanistic studies get cited as reference points for years.

For career purposes, JBC is universally recognized in biochemistry. It's not a prestige journal like Cell or Nature, but a strong JBC paper demonstrates rigorous biochemistry in the field's community journal.

The 20-year arc tells a story that the recent numbers alone don't capture. JBC's IF was nearly 6.0 in the mid-2000s, then declined steadily to ~4.0 by the mid-2010s as competition from newer open-access journals intensified. The pandemic produced a brief recovery to ~5.5 in 2021, but the journal has settled back to 3.9, its lowest point in two decades. That said, JBC's cumulative h-index of 567 and 283,206 total citations reflect a journal with enormous historical weight. The IF captures recent performance; the citation history captures the journal's deep influence on biochemistry.

JBC is known for relatively fast turnaround. The first editorial decision typically arrives within 30 days, which is faster than many comparable journals. If revisions are requested, the journal gives authors about 2 months to resubmit. Total time from submission to online publication is usually 4-6 months, which is competitive for the field.

JBC has been fully open access since January 2021. All published articles are freely available without a subscription. The APC is approximately $2,000-$2,500, which is lower than many comparable OA journals (for example, Nature Communications charges ~$5,990). ASBMB members receive a discount on the APC. The OA transition has increased JBC's discoverability and download rates, even as the IF has declined.

Submit if:

• the paper is rigorous biochemistry with clear mechanistic contribution
• you value fast, constructive peer review from field experts
• the work is strong within biochemistry but doesn't reach Cell/Molecular Cell breadth
• you want the ASBMB community's flagship journal

Think twice if:

• the finding has cross-disciplinary significance (Molecular Cell, EMBO Journal, or Nature)
• the paper is primarily cell biology or genetics without a biochemistry core
• a specialty journal would give better field-specific visibility

A JBC biochemistry depth check can help assess whether the mechanistic evidence package is strong enough for JBC.

JBC's IF of 3.9 is the number everyone looks at. It's the wrong number. The metric that actually tells JBC's story is its cited half-life: 18.3 years. That's the longest of any journal we've analyzed across all fields.

What does that mean in practice? JBC papers published in 2006 are still being actively cited in 2024. That's not a quirk, it's the nature of what JBC publishes. Enzymology, protein biochemistry, metabolic pathway characterization, this is foundational work that doesn't expire when a new technique comes along. It becomes the reference point that everyone cites for decades.

JBC's 283,206 total citations and 1,057 articles per year tell the same story from a different angle. This isn't a journal that chases flashy results, it's where the biochemistry community deposits its foundational knowledge. The IF understates JBC's importance because it only measures a two-year window, and JBC's real value shows up over 10--20 years.

If you're doing work that you expect to be cited as a reference point, enzyme kinetics, protein structure-function relationships, metabolic characterization, JBC is exactly where it belongs. The IF won't impress a hiring committee that only reads numbers, but biochemists know what a JBC paper means.

In our pre-submission review work on manuscripts targeting Journal of Biological Chemistry, three patterns account for most of the desk rejections we see.

Papers that describe a biological observation without mechanistic explanation. JBC is a biochemistry journal in a specific sense, it publishes molecular mechanism. Observation-first papers that document a phenotype, correlation, or cellular behavior without explaining the biochemical mechanism responsible consistently struggle at review. The journal has a clear expectation that biochemical papers will include in vitro reconstitution of the key activity, structure-activity analysis, or kinetic characterization that demonstrates mechanistic understanding rather than just functional consequence. Authors from cell biology or genetics backgrounds sometimes underestimate this expectation and submit papers where the mechanism section relies primarily on genetic perturbations without the biochemical depth JBC reviewers expect.

Incremental biochemistry without the community significance to justify the journal. Despite a 50% acceptance rate, JBC is selective about what constitutes a genuine biochemical advance. We see papers where the contribution is technically correct but represents a small extension of well-established biochemistry, a new substrate for a known enzyme family, a modest kinetic characterization of a variant, an additional binding partner in a known complex. The journal's acceptance rate is higher than elite journals, but it is not a catch-all venue. The paper needs to add something meaningful to the biochemical understanding of the system or protein class, not just another data point in an already well-characterized area.

Papers where the biochemistry is incidental to a biological discovery. JBC is not the right home for papers where the primary contribution is a biological or cell biological finding and the biochemistry is done to support it. We see submissions where an exciting cellular or organismal phenotype is accompanied by biochemical characterization, but the paper is really a cell biology or genetics paper. Those papers tend to score lower on JBC's biochemical depth criteria and would be better placed in Journal of Cell Biology, Cell Reports, or a disease-specific journal where the biological finding can stand as the primary contribution.